{
  "docId": "019de075-03fc-75b4-9b20-1ad4baba72b2",
  "docSlug": "9cc11288f450409d9a3eef75fc694943",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-05-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 16,
  "pageCount": 39,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "appendix_data",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 20,
  "notes": "The slide details the transition from the All-Treated Population (N=35) to the NSCLC Response-Evaluable Population (N=21) through back-fill expansion.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-03fc-75b4-9b20-1ad4baba72b2/16",
  "deckHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2",
  "deckJsonHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2.json",
  "deckAnchorHref": "/decks/019de075-03fc-75b4-9b20-1ad4baba72b2#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.45,
        "w": 0.84,
        "x": 0.08,
        "y": 0.36
      },
      "kind": "diagram",
      "text": "Flow diagram showing dose levels, back-fill additions, and response-evaluable population counts.",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ef33e206-bb65-42ea-9603-6d76160f66e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.08,
        "y": 0.21
      },
      "kind": "paragraph",
      "text": "All-Treated Population (N = 35)",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9ad229f2-b421-4eee-a368-f67682e830fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.84,
        "x": 0.08,
        "y": 0.86
      },
      "kind": "source-note",
      "text": "Data as of 13 Sep 22, for patients treated by 01 Sep 2022. mg, milligram; NSCLC, non-small cell lung cancer; QD, once daily. a First response evaluation is pending for 6 patients...",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "fbe4bdce-c2fe-4d07-ac25-8df2b6726d0c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.07,
        "y": 0.08
      },
      "kind": "title",
      "text": "Cohort Accrual | ARROS-1 Phase 1 Dose-Escalation",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "405bc305-7bde-4a63-a2d4-3f1df90c8b99",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 24,
      "from": 13,
      "beatId": "38e371b8-b1f4-4700-814e-96d0791c56bb",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The document showcases preclinical and clinical data for NVL-520 and NVL-655.",
      "position": 4,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 26,
      "from": 7,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "fe9c6514-22f1-4979-9b36-391b44fa3c8a",
      "evidence": "The document presents the limitations of current therapies and the potential benefits of Nuvalent's targeted therapies.",
      "position": 0,
      "objective": "The cost of inaction in addressing kinase resistance and selectivity challenges",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    },
    {
      "to": 24,
      "from": 13,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "2038f58a-de52-4ce2-87cd-b26435c6bd24",
      "evidence": "The document showcases preclinical and clinical data for NVL-520 and NVL-655.",
      "position": 1,
      "objective": "The potential for quick wins with Nuvalent's targeted therapies",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}